We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Summit Therapeutics Inc.

that you should be aware of before investing here. NasdaqGM:SMMT Earnings Per Share Growth as at Apr 2025 Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

The UK's new car market experienced a 12.4% increase in March 2025, reaching 357,103 units, according to the Society of Motor ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

The number of cars being used on UK roads grew to record levels in 2024, up 1.3% or 470,556 units to 36,165,401.

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off ...